In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ... The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting. Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting. Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.